A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes

What Was Tested

The paper reports a study of Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.

Who Took Part

According to the abstract, 296 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

This 29-week, double-blind, placebo-controlled study randomized 296 patients to pramlintide or placebo as an adjunct to insulin.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Amylin (Islet Amyloid Polypeptide) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Amylin (Islet Amyloid Polypeptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Amylin (Islet Amyloid Polypeptide) group a baseline to be compared against.

Insulin was subsequently adjusted to optimize glycemic control.

End points included safety and change in HbA1c (A1C), postprandial glucose, insulin, weight, and tolerability.

What Was Measured

The subject headings attached to it are Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Eating, Glycated Hemoglobin, Insulin and Islet Amyloid Polypeptide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) in 296 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2006 (Diabetes care), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.